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Abstract 
Renal transplantation is the optimum treatment for end-stage renal failure. B cells have been 
identified in chronic allograft damage (CAD) and associated with the development of tertiary 
lymphoid tissue within the human renal allograft. We performed renal transplantation in mice 
to model CAD and identified B cells forming tertiary lymphoid tissue with germinal centres. 
Intra-allograft B220+ B-cells comprised of IgMhigh CD23- B cells, IgMlo CD23+ B cells and IgMlo 
CD23- B cells with elevated expression of CD86. Depletion of B cells with anti-CD20 was 
associated with an improvement in CAD but only when administered after transplantation and 
not before. Isolated intra-allograft B cells were cultured and shown to synthesise multiple 
cytokines, the most abundant of these were GRO-α (CXCL1), RANTES (CCL5), IL-6 and 
MCP-1 (CCL2). Tubular loss was observed with T cell accumulation within the allograft and 
development of interstitial fibrosis, whilst type III collagen deposition was observed in areas of 
F4/80+ macrophages and PDGFR-β+ and transgelin+ fibroblasts, all of which were reduced by 
B cell depletion. We have shown that intra-allograft B cells are key mediators of CAD. B cells 
possibly contribute to CAD by intra-allograft secretion of cytokines and chemokines. 
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Introduction 
Renal transplantation is the optimum treatment for many patients with end-stage renal failure 
(1). A major challenge of renal transplantation is chronic allograft damage (CAD) 
characterized by interstitial fibrosis and tubular atrophy. The pathophysiology is poorly 
understood and multiple cell mediators and mechanisms are involved (2). 
B cells have been identified in biopsies of renal transplants with stable function (3), in 
the context of acute rejection (4, 5), and chronic damage (6). However other studies have not 
correlated the presence of B cells to be detrimental (7), and B cells have been associated 
with the development of ectopic lymphoid tissue, also termed tertiary lymphoid tissue (TLT), 
within the human renal allograft (8). Although TLT in humans has been found in multiple 
chronic inflammatory disease states (9), the role of intra-allograft B cells and their significance 
have not been well explored (10). 
The presence of B cells infiltrating inflammatory tissue in other models of disease has 
been associated with worse injury. Early depletion of B cells in myocardial infarction reduced 
the number of B cells recruited to the tissue and this was associated with significant 
improvement in post infarction cardiac function, furthermore recruitment of macrophages into 
the tissue and subsequent fibrosis were reduced (11). In a similar manner liver fibrosis was 
attenuated in mice deficient in intra-hepatic B cells (12), and CD19 deficient mice developed 
less Beomycin-induced pulmonary-fibrosis (13). 
However the non-specific depletion of B-cells has been met with caution as the 
presence of regulatory B cells has been associated with protection from disease in some 
models (14, 15). Indeed a clinical study of B cell depletion as induction to renal 
transplantation was associated with a significant increase in acute rejection (16). There has 
been increasing interest in the functions of B cells beyond their role in antibody production, 
including cytokine-mediated effects in human disease (17, 18). In this report we have shown 
that intra-allograft B cells are key mediators of CAD and that B cells possibly contribute to 
CAD by intra-allograft secretion of cytokines and chemokines. 
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Materials and Methods 
 
Mice and renal transplantation 
Experiments performed under a UK Home Office Project Licence, granted under the Animal 
(Scientific Procedures) Act 1986 and approved by the University of Edinburgh ethical review 
committee. Eight-week old male C57BL/6 and BALB/c mice were obtained from Charles 
River, and C57BL/6BM12 colonies maintained in specific pathogen-free conditions in the 
Biological Research Resources Centre Edinburgh. Survival was greater than 80% for study 
groups. Anaesthesia was with intraperitoneal ketamine (75mg/kg) and medetomidine 
(1mg/kg), the donor kidney was perfused with cooled University of Wisconsin solution (Belzer 
Bridge to Life), the surgical technique was as previously reported (19). Renal transplantation 
was performed with a mean warm ischemic time of 30min. The donor ureter was 
anastomosed to recipient bladder. Anaesthesia was reversed with subcutaneous injection of 
atipamezole (1mg/kg) and buprenorphine (0.05mg/kg) for analgesia, with 1ml of 0.9% NaCl 
injected subcutaneously. The mouse was recovered and monitored in a warming cabinet at 
28°C. A single intact native kidney was left in situ and the model was not transplant-
dependent. To model CAD, heterotopic kidney transplantation was performed from a 
C57BL/6BM12 (H-2BBM12) donor into a C57BL/6 (H-2B) recipient as previously described (19, 
20). To model acute rejection a C57BL/6BM12 donor kidney was transplanted into a BALB/c (H-
2d) recipient. For the isograft group C57Bl/6 kidneys were transplanted into litter mates. 
 
B cell depletion 
B cell depletion was performed by a single tail vein intravenous injection of 300µg anti-mouse 
CD20 mAb (18B12, IgGµ2a; Biogen Idec, San Diego, CA) in 200µl 0.9% NaCl, as described 
previously (21). Control placebo treated mice received anti-human anti-CD20 mAb 
(Rituximab; Biogen Idec). 
 
Histology,  
Immunohistochemistry, immunofluorescence methods and microscopy equipment are given 
in supplementary materials. Tubules within the cortex (x200 magnification, ten fields) were 
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counted using ImageJ software (Cell counter plugin; ImageJ 1.22o; National Institutes of 
Health, Bethesda, US). B220+ B cell, CD3+ T cells, F4/80+ macrophages, picrosirius red, 
collagen III, SM22, PDGFR-β and α-SMA were expressed as average % area per high 
powered field (x200 magnification, ten fields) using a verified methodology of positive staining 
using Colour Range tool on Photoshop CS6 Extended (Version 13.0.6; Adobe Systems 
Europe) (22). Absolute numbers of LYVE1+ lymphatic vessels and PNAd+ high endothelial 
venules through the whole tissue section were expressed per mm2 of the total tissue area 
calculated using ImageJ software. Pathological grading of T cell inflammation based on 
modified average T-score for each kidney (x200 magnification, ten fields, each given t-score 
of greatest degree per field) (23). T-score was calculated by T0 = no mononuclear cells in 
tubules, T1 = foci with 1-4 cells/tubular cross-section (or 10 tubular cells), T2 = foci with 5-10 
cells/tubular cross-section, T3 = foci with >10 cells/tubular cross-section or the presence of at 
least two areas of tubular basement membrane destruction. 
 
Kidney digestion  
Single cell suspension from kidney digestion was prepared by mechanically fragmenting 
tissue using a No. 23 scalpel (Swann-Morton, UK) into IMDM (GIBCO, Life technologies, UK), 
5% Fetal calf serum (Biosera Europe, France) and 1% Penicillin/Streptomycin (PAA 
Laboratories GmbH, Austria). The homogenate was centrifuged (5min, 300g) and re-
suspended in 2ml Hanks Buffer (PAA Laboratories GmbH, Austria) containing 1.6mg/ml 
collagenase B (Roche Diagnostics GmbH, Mannheim, Germany) and 100g/ml DNAse I 
(Roche Diagnostics GmbH, Mannheim, Germany), and incubated at 37°C for 30min with 
occasional rotational mixing. The homogenate was passed through a 40µm cell strainer (BD 
Biosciences, USA) and cells were centrifuged (5min, 300g). Red blood cells were lysed by 
incubation on ice with red cell lysis buffer (Sigma Aldrich, USA) 10min. 
 
Flow cytometry  
For splenocyte and allograft lymphocyte flow cytometry cell analysis 1x106 cells were stained 
for 30min at 4°C with primary antibodies given in supplementary materials. Cells were 
washed and DAPI added immediately before analysis using BD FACSDIVA version 6.1.3 on 
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a LSR Fortessa (BD Biosciences, USA). Analysis was gated on collecting 10,000 live B cell 
events. Post acquisition data analysis was performed using FlowJo version 10.6 (TreeStar 
Inc., USA). For peripheral flow cytometric analysis 12.5µl of peripheral blood was obtained by 
tail vein bleeding and added to 3.8% sodium citrate; aforementioned primary antibodies in 1% 
PBS were added and stained for 30min at 4°C before FACS lysing solution (BD Biosciences, 
San Jose, USA) was added before data acquisition along with CountBright Beads (Invitrogen, 
USA). See supplementary materials for cell sorting methods. 
 
Circulating immunoglobulin titration 
Blood was obtained by cardiac puncture with a 21G needle (Microvette 600, Germany) and 
serum was separated by centrifugation (10,000G, 5min) and frozen at -20°C till use. 
Determination of serum antibody concentrations was performed with a Luminex multiple 
analyte immunoglobulin profiling magnetic bead assay (Procartaplex, eBioscience, UK), prior 
to incubation with the bead assay serum was diluted 1:10,000 with universal buffer supplied 
within the assay kit. Luminex data acquisition was performed on a Bio-plex 200 system (Bio-
Rad, USA) and analysis was performed using Bio-plex manager software (Version 6.0, Bio-
Rad Labs Inc, USA). 
 
Anti-donor antibody determination 
Allospecific antibodies in sera of transplant recipients were assessed using indirect flow 
cytometry. Serum was assayed for anti-donor antibodies by their ability to bind C57BL/6BM12 
splenocytes using flow cytometry. Splenocytes (0.5 x 106) were incubated in 50µL Dulbecco’s 
PBS (PAA Laboratories GmbH, Austria) containing 1:20 recipient serum for 30min at 4°C 
followed by washes with PBS. Goat F(ab')2 polyclonal anti-IgG-FC-phycoerythrin (ABCAM, 
Cambridge, UK) was added and further incubated for 30min. Fluorescence analysis was 
determined by flow cytometry using a LSR Fortessa (Becton Dickinson, USA) and median 
fluorescence intensity measured post-acquisition using FlowJo (Tree Star Inc., USA). 
Conditions were performed in technical triplicates for samples derived from individual mice. In 
a similar manner auto-antibodies in the sera of transplant recipients were assessed using 
permeabilised cells. Splenocyte permeabilisation (Foxp3 Fixation/Permeabilization Set, 
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eBioscience) was performed prior to incubation with diluted recipient serum. 
 
B Cell cytokine assay 
Following FACS B cell isolation 2.5 x105 B cells were incubated in a 96-well plate in 250µl of 
IMDM GIBCO, Life technologies, UK), 10% FCS (Biosera Europe, France) and 1% Penicillin 
and Streptomycin (PAA Laboratories GmbH, Austria) for 72hr. In separate wells B-cells were 
stimulated with ionomycin 1µg/ml and PMA 20ng/ml or 2.5 x105 γ-irradiated C57BL/6BM12 
splenocytes (Caesium-137, 30Gy). Determination of the presence of multiple cytokines was 
performed with a Luminex multiple analyte cytokine profiling magnetic bead assay 
(eBioscience, UK, or Bio-Rad, UK). Luminex data acquisition was performed on a Bio-plex 
200 system (Bio-Rad, USA) and analysis was performed using Bio-plex manager software 
(Version 6.0, Bio-Rad Labs Inc, USA). 
 
Statistical analysis 
Data expressed as mean (SEM, standard error of the mean) unless otherwise stated. ANOVA 
(within groups and between multiple groups) with post hoc Bonferonni test, unpaired student’s 
t-test (for parametric data-sets) and Mann-Whitney U tests (for non-parametric), were 
performed using Prism 5 for Mac OS X software (GraphPad Software Inc., La Jolla, Ca, 
USA). A p-value of less than 0.05 was considered significant. 
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Results 
Mature B cells are recruited to the renal allograft 
In CAD a progressive loss of tubules occurred over a twelve-week period, no difference in the 
number of healthy tubules between native kidneys and isograft kidneys was observed (Figure 
1A, CAD vs Isograft ANOVA p<0.0001). The loss of nephron mass was accompanied by 
interstitial fibrosis, identified by picrosirius red staining of fibrillar collagen within the renal 
parenchyma. Following isograft transplantation minimal fibrosis developed with scarring being 
significantly greater in CAD kidneys (Figure 1B, CAD vs Isograft ANOVA p<0.0001). There 
was a progressive accumulation of B220+ B cells within the allograft predominantly originating 
in a perivascular location, peaking at 12 weeks, whereas isograft kidneys were devoid of B 
cells (Figure 1B, ANOVA p<0.0001).  
 
B cells form germinal centres and tertiary lymphoid tissue 
Immunofluorescence confirmed B cells forming GL7+ germinal centres and presence of 
CD138+ plasma cells in 12-week allograft kidneys (Figure 1C). The development of TLT was 
further supported by the presence of LYVE1+ lymphatics and PNAd+ high endothelial venules 
(Figure 1C). Compartmentalization of intra-allograft B cells into TLT was suggested by the 
presence of B cells that were either IgMhigh CD23-, IgMlo CD23+ or IgMlo CD23- (Figure 2A and 
2B) suggesting some similarities with those found in spleen and found in a similar population 
distribution (Figure 2C). In addition a greater percentage of intra-allograft B cells expressed 
CD86 (B7-2) than naïve spleen B cells (Figure 2C, ANOVA p<0.0001), though there was no 
difference in CD80 expression between allograft B cells, naïve or allograft spleen B cells.  
 
B cell depletion reduces interstitial fibrosis and tubular loss 
To investigate whether the progression of CAD could be modified B cell depletion at 4 weeks 
after transplantation was performed. A monoclonal anti-CD20 approach was used to replicate 
human studies (16). This strategy effectively depleted peripheral blood CD45.2+ B220+ B cells 
compared to placebo anti-human anti-CD20 (Rituximab) treatment (Figure 3A). Peripheral 
blood B cells remained significantly suppressed for up to 4 weeks (Figure 3B, 8 weeks 
p=0.004, 12 weeks p=0.0012, student t-test) and intra-allograft B cells were also reduced 
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(Figure 3C, 8 and 12 weeks p=0.0001, U test). This intervention reduced interstitial fibrosis 
(Figure 4A and 4D, p=0.013, U test) and protected kidneys from tubular loss at 12 weeks 
(Figure 4B and 4D, p=0.013, U test) compared to placebo. Renal allograft expression of 
kidney injury molecule-1 (KIM-1) mRNA at 8 weeks was significantly reduced by B cell 
depletion at 4 weeks (Figure 4C, p=0.0173, U test).  In comparison, B cell depletion 1 week 
prior to transplantation had no effect on the development of CAD (Figure S1, picrosirius red 
ANOVA p=0.0812, tubule count p=0.6521). 
 
B cells depletion reduces formation of tertiary lymphoid tissue 
B cell depletion at four weeks after transplantation inhibited the formation of GL7+ germinal 
centres (Figure 5A, 8 weeks p=0.025 and 12 weeks p=0.0263, U test). Expansion of 
lymphatic vessels was noted between isograft and placebo treated allograft kidney at 12 
weeks (Figure 5B, U test p=0.012), however B cell depletion had no significant effect on 
lymphatic numbers, though there was a trend towards reduction (Figure 5B). The ectopic 
development of PNAd+ high endothelial venules, a component of TLT, was inhibited by B cell 
depletion (Figure 5C, 8 weeks p=0.044 and 12 weeks p=0.027, U test). 
 
The effect of B cell depletion in CAD model is predominantly independent of antibody 
Transplanting a C57BL/6 kidney into a BALB/c recipient is known to result in IgG donor-
specific antibody and this was used as a positive control (Figure 6A and 6B, p<0.0001, 
ANOVA) (24). In CAD mice, serum concentration of IgM and total IgG were elevated at 4 
weeks following allograft transplantation compared to naïve levels (Figure 6A). The elevated 
IgG isotype in CAD mice appeared to be of IgG1 and IgG3 subclass, IgG2a concentration 
was not elevated in C57BL6 recipients; however IgG1, IgG2a and IgG3 were elevated in 
BALB/c recipients (Figure S2). No IgG reactivity was observed against fresh C57BL/6BM12 
splenocytes in serum from C57BL/6 recipients, compared to a significant increase in the 
median fluorescence intensity (MFI) cell surface IgG binding following incubation with serum 
from BALB/c recipients (Figure 6B, p<0.0001, ANOVA). To investigate auto-antibody 
generation, C57BL/6BM12 splenocytes were permeabilised prior to incubation with serum. 
Although an increase in MFI of IgG was observed in CAD mice compared to with naïve 
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C57BL serum, B cell depletion after transplantation had no affect on the presence of auto-
reactive IgG (data not shown). IgG was apparent in the allograft tissue (Figure 6C), however 
IgM did not appear to be present within the allograft other than that expressed on the surface 
of B cells. B cell depletion by anti-CD20 did not reduce the amount of IgG in the CAD kidney 
either at 8 or 12 weeks post transplantation (Figure 6C, 8 weeks p=0.4848 and 12 weeks 
p=0.2403, U test). Lastly the complement split product C4d was not detected in rejecting 
allografts further suggesting that antibody-mediated rejection is not involved in this model of 
CAD. Glomerulopathy was not a feature, with normal glomeruli demonstrated in the presence 
of IFTA (Figure 4D). 
 
T cell accumulation is reduced by B cell depletion 
T cells were identified in perivascular regions as well as dispersed throughout the kidney 
parenchyma where they infiltrated glomeruli and tubules (Figure 7A). B cell depletion at four 
weeks after transplantation significantly reduced T cell density (Figure 7B, 8 weeks p=0.0052 
and 12 weeks p=0.0002, U test), and the T-score (reflecting the level of pathological T cell-
mediated injurious tubulitis) at 8 weeks (Figure 7B, 8 weeks p=0.045, U test). T cells could be 
identified crossing the basement membrane of tubules and invading renal tubules on 
transmission electron microscopy (Figure 7C). However few GR1+ neutrophils were identified 
in the allograft and B cell depletion had no effect on their presence (Figure S3, 8 weeks 
p=0.2365 and 12 weeks p=0.4212, U test). 
 
To identify the mechanism of T cell recruitment we isolated intra-allograft B cells from CAD 
kidneys at 4 weeks following transplantation. Ex vivo culture revealed B cells were activated 
to synthesize T cell chemokines, including GRO-α (CXCL1), RANTES (CCL5) and IP-10 
(CXCL10) (Fig 8A, p=0.0035, p=0.0005, p=0.0093 respectively, ANOVA). Generation of these 
chemokines was not dependent on re-stimulation and levels were significantly higher than 
produced by naive B cells stimulated by ionomycin and phorbitol myrisate acetate. Isolated 
intra-allograft B cells also secreted multiple pro-inflammatory cytokines, including IL-6, IL-18, 
and TNF-α (Figure 8A, p<0.001, ANOVA). In addition IL-10 was assayed but was not 
detected in stimulated B cell supernatant (data not shown). To confirm the generation of 
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these cytokines in vivo by B cells, intra-allograft B cells were sorted into pure CD45.2+ B220+ 
populations; mRNA was immediately isolated and analyzed for the most abundantly 
expressed cytokines (Figure 8B). 
 
Reduced fibrosis is associated with lower monocyte and fibroblast density 
Type III collagen was detected in this model of CAD (Figure 9A). Late B cell depletion 
reduced type III collagen expression in the allograft kidney at both eight and twelve weeks 
(Figure 9B, both p<0.0001, U test), in keeping with reduced picrosirius red staining (Figure 
4A). Intra-allograft F4/80+ cells were reduced by late B cell depletion after transplantation 
(Figure 9B, 8 weeks p=0.0007 and 12 weeks p<0.0001, U test). Interestingly there was no 
difference in α-SMA+ myofibroblasts between placebo and B cell depletion (Figure 9B, 8 
weeks p=0.25 and 12 weeks p=0.82, U test); α-SMA was restricted to intra-renal vessels and 
was not identified in proximity to type III collagen on serial sections (Figure 9A). Additionally 
the level of transgelin (Figure 9B, 12 weeks p<0.0001, U test) and PDGFR-β expression 
(Figure 9B, 8 weeks p=0.420 and 12 weeks p<0.0001, U test) were significantly reduced in B 
cell depletion and followed the same pattern as type III collagen in the renal parenchyma 
(Figure 9A). 
 
The supernatant of ex vivo cultured isolated intra-allograft B cells was analysed to explore the 
role of activated B cells in fibrosis and significant levels of monocyte cytokines MCP-1 
(CCL2), MCP-3 (CCL7) and MIP-2 (CXCL2) were found (Figure 10A, p=0.0401, p=0.0334, 
p=0.0002 respectively, ANOVA). Furthermore stimulation of B cells with irradiated 
C57BL/6BM12 splenocytes stimulated the synthesis of TGF-β1, MIP-1α and MIP-1β (Figure 
10A, p=0.0074, p=0.0232, p=0.0298 respectively, ANOVA); mRNA expression of the most 
abundant cytokines was confirmed in freshly isolated B cells (Figure 10B). 
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Discussion 
In this study we have demonstrated a key function of intra-allograft B cells to be the secretion 
of cytokines.  The depletion of intra-allograft B cells reduced T cell accumulation and 
fibroblastic cells that mediate interstitial fibrosis. In addition, intra-allograft B cells expressed 
the co-stimulatory molecule, CD86, as a marker of an antigen-presenting cell. CD86 
expression by antigen presenting cells play an important role in co-stimulation for T cell 
activation (25). Recent study of acute rejection in human renal transplant biopsies correlated 
the presence of CD20+ B cell clusters with steroid resistant T cell mediated cellular rejection 
(5); intriguingly B cell clusters have also been identified in chronically rejected transplants (26, 
27), and in relation to lymphatic neoangiogenesis (28), as such, much is still unknown about 
the role of intra-allograft B cells in transplantation. In this model B cells appear as nodular 
infiltrates in a perivascular distribution, mimicking that described in human studies (3, 26). 
These results are in agreement with previous studies using this donor and recipient 
combination, modeling rejection in both cardiac (29)  and renal transplantation (20). 
Furthermore the compartmentalization of intra-allograft B cells into TLT was suggested by the 
presence of B cells that expressed surface markers which had some similarities with those 
found in spleen (30). 
Type III collagen is a fibrillar protein that is synthesized in inflammation and present in 
chronic rejection of human renal allografts (31), and was detected in this model. Despite the 
association between intra-allograft B cells and interstitial fibrosis, this was not mediated 
through α-SMA-expressing myofibroblasts, although the expression of α-SMA is associated 
with a great degree of variability (32, 33). Other mechanisms promoting fibrosis were 
therefore examined: activated pericytes express platelet derived growth factor receptor-β 
(PDGFR-β) and can differentiate into fibroblasts (34). Transgelin is an actin stress fibre-
associated protein and an early marker of smooth muscle cell differentiation, and is 
associated with renal fibroblast activation (35). Both transgelin and PDGFR-β, which may be 
alternative markers of fibroblast activation, were expressed in areas of tubular atrophy and we 
speculate that B cells could potentially drive fibrocyte or fibroblast activation through these 
mechanisms. 
Increasingly it is recognized that B cells may be an important source of pro-
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inflammatory and anti-inflammatory cytokines (18). We found that intra-allograft B cells 
synthesise GRO-α, IL-6, RANTES, CXCL-10 and MCP-1 in the greatest abundance and that 
B cells can be further induced by re-stimulation with donor antigens. The most highly 
synthesized of these cytokines was GRO-α which has been reported to be a major stimulus 
for neutrophil chemotaxis (36), however there were very few neutrophils present in the 
allograft tissue, suggesting an alternative role for this cytokine. Recently GRO-α has been 
shown to play a role in angiogenesis (37), therefore it is hypothesized that GRO-α plays a role 
in TLT development as B cell depletion inhibited the formation of germinal centres, high 
endothelial venules and lymphatic expansion. The presence of B cells at sites of inflammation 
has been associated with fibrosis. Specifically following myocardial infarction B cells induced 
local macrophage recruitment through MCP-3 (CCL7) production (11), similarly we found B 
cells synthesise this cytokine within the allograft however to a lesser degree than MCP-1 
(CCL2). 
An interesting feature of this model of CAD is the generation of IgG auto-antibodies 
that appear to be IgG1 or IgG3 isotypes. Following C57BL/6BM12 cardiac transplantation in 
C57BL/6 recipients IgG auto-antibodies have been observed (38). The IgG1 isotype is not 
capable of fixing complement and in a cardiac allograft model this isotype was not capable of 
mediating rejection, however IgG1 may stimulate endothelial cells to produce CXCL1 and 
CCL2 which are potent chemo-attractants to neutrophils and macrophages (39). Potentially 
intra-allograft B cells promote fibrosis by recruiting monocytes into the allograft, thereby 
supporting macrophage-mediated fibrosis or directly activate profibrotic cells through TGF-β1.  
Intriguingly in patients that develop chronic renal transplant rejection de novo auto-antibodies 
have been detected (40). Serum IgM was attenuated in B cell depleted animals however no 
significant change in isotype switched Ig or IgG deposition in the allograft was found. It is 
possible that even if the antibodies were not complement fixing they may still play a role in 
CAD by promoting Fc-receptor mediated functions in cells such as macrophages. 
B cell depletion was performed by monoclonal anti-CD20 antibody depletion, with the 
human counterpart that has been widely used in human disease and its safety profile proven. 
However when used in depletion prior to renal transplantation this was shown to significantly 
increase acute rejection (16). Some evidence in human studies supports the hypothesis that 
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B cell depletion in late allograft failure may be beneficial beyond targeting antibody-mediated 
rejection. In small series and case studies Rituximab, in addition to other immuno-modulatory 
therapies, has been administered to patients with late allograft failure with improvement or 
return of function without any change in circulating DSA levels (41-44). One might speculate 
that this protection is against intra-graft B cell production of the cytokines as described in our 
model.  
Another issue raised in this study is that depletion of B cells prior to transplantation 
had no affect on CAD whereas depletion at four weeks post transplantation inhibited CAD.  
Paradoxically in patients with long-term tolerance a B cell specific signature has been 
identified (45), however this was in peripheral blood samples. The allograft B cells in this 
study did not produce interleukin-10, this argues against an anti-inflammatory role for them. 
TGF β was produced by allograft B cells and has been associated with tolerance (46), 
however it also well characterized as a profibrotic cytokine (47). Thus ‘regulatory B cells’ are 
under investigation and this highlights the complex nature of B cell compartments and the 
challenge in determining their modes of action.    
Here we have shown that intra-allograft B cells are a major source of cytokines that 
may orchestrate T cell and monocyte recruitment and thus contribute to chronic damage and 
scarring in the renal allograft. These findings suggest that intra-allograft B cells per se and 
their cytokine and chemokine pathways represent potential novel therapeutic target for 
therapy in human renal transplantation.  
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Figure Legends 
 
Figure 1: B cells accumulate within transplanted kidneys undergoing chronic allograft 
damage (CAD)(C57BL/6BM12!C57BL/6).  
(A) Representative histology of paraffin-embedded allograft transplant kidney sections. 
Haemotoxylin and eosin for tissue architecture, collagen with picrosirius red (red), B220+ B 
cells (brown). (B) Quantification of the number of tubules, density of collagen and B cells in 
transplanted kidneys. Ten micrographs at x200 magnification were analyzed (n=6 mean 
(SEM), ANOVA and Bonferonni post hoc between groups at time points. *p<0.05; **p<0.01). 
(C) Definition of CAD B cell infiltrates 12 weeks post transplantation in immunofluorescent 
micrographs identifying GL7+ germinal centres and CD138+ plasma cells, and tertiary 
lymphoid tissue development with PNAd+ high endothelial venules and LYVE1+ lymphatic 
vessels.  
 
Figure 2: The phenotype of allograft (C57BL/6BM12!C57BL/6) B cells by flow cytometry.  
(A) Gating of B cells from allograft kidney digest. Intra-allograft B cells isolated following 
allograft kidney digestion then B220+ magnetic bead enrichment prior to fluorescence 
activated cell sorting by B220+ CD45.2+ DAPI- for mRNA extraction and cell culture 
experiments. (B) CAD intra-allograft B cell phenotype were analysed on flow cytometry and 
compared to naive spleen B cells. (C) Frequency of gated B cells (n=6, mean (SEM), ANOVA 
and Bonferonni post hoc between groups. **p<0.01). 
 
Figure 3: Anti-CD20 after transplantation depletes intra-renal B cells in chronic 
allograft damage (C57BL/6BM12!C57BL/6) 
(A) Flow cytometry gating of blood B cells prior to and following anti-mouse anti-CD20 or anti-
human anti-CD20 (Rituximab). (B) Absolute count of blood B cells were determined in mice 
treated prior to, or 4 weeks after, transplantation (n=6, mean (SEM), ANOVA and Bonferonni 
post hoc between groups at single time points. **p<0.01; ***p<0.001). (C) Quantification of 
the immunohistochemistry micrographs of allograft density of B220+ B cells following anti-
mouse anti-CD20 or anti-human anti-CD20 (Rituximab). Ten micrographs at x200 
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magnification were analyzed (n=6 mean (SEM), Mann-Whitney U test. ***p<0.001). 
 
Figure 4: B cell depletion reduces chronic allograft damage (C57BL/6BM12!C57BL/6). 
(A) Quantification of allograft density of collagen following picrosirius red staining following 
anti-mouse anti-CD20 or anti-human anti-CD20 (Rituximab). (B) Quantification of the number 
of tubules by haemotoxylin and eosin staining following treatment. Ten micrographs at x200 
magnification were analyzed (n=6, mean (SEM), Mann-Whitney U test between groups at 
single time points. *p<0.05; **p<0.01). (C) Allografts at 8 weeks after transplantation from 
mice depleted at 4 weeks of B cells had a decreased expression of CD20 and Kim-1 mRNA 
(n=8, assay in triplicate, mean (SEM), Mann-Whitney U test. *p<0.05). (D) Representative 
histology of paraffin-embedded transplant kidney sections. Fibrosis identified by collagen with 
picrosirius red, tubular atrophy demonstrated in untreated and placebo treated tissue. 
 
Figure 5: Reduction in tertiary lymphoid tissue development. 
(A) Representative immunohistochemistry of GL7+ germinal centres (brown) counted per total 
tissue area section. (B) Absolute numbers of LYVE1+ lymphatic vessels (brown) per total 
tissue area section. (C) Absolute numbers of PNAd+ high endothelial venules (brown) per 
total tissue area section in anti-CD20 or placebo (Rituximab) treated allograft kidneys (n=6, 
mean (SEM), Mann-Whitney U test. *p<0.05). 
 
Figure 6: CAD is not primarily mediated by donor-specific immunoglobulin 
C57BL/6BM12 donor kidneys transplanted in to C57BL/6 allograft recipients 
(C57BL/6BM12!C57BL/6) or BALBc allograft recipients (C57BL/6BM12!BALB/c). (A) Serum 
concentrations of IgM and total IgG from naïve and transplant recipient mice were measured 
(see supplemental table 1 for absolute values)(n=5, assay in duplicate, mean (SEM), ANOVA 
and Bonferonni post hoc between groups. *p<0.05; **p<0.01; ♯p<0.001 against all groups). 
(B) Flow cytometry of live splenocytes incubated with transplant recipient serum to detect 
donor-specific IgG, quantification by median fluorescent intensity (n=6, assay in triplicate, 
error bars median and interquartile-range, ANOVA and Bonferonni post hoc between groups. 
***p<0.001). (C) Intra-allograft IgG content with representative immunofluorescence 
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comparing naïve kidney and of CAD allograft 12 weeks post-transplantation demonstrating 
deposited IgG (green) and B cells bearing IgG. Quantification of IgG+ micrographs following 
treatment (n=6, mean ± SEM, Mann-Whitney U test, N.S.). 
 
Figure 7: B cell depletion reduces T cell accumulation. 
(A) Representative immunohistochemistry of CD3+ infiltrating T cells (brown). T cells identified 
invading glomeruli (hollow arrows) and tubules (block arrows). (B) Quantification of the 
immunohistochemistry micrographs to determine allograft density of CD3+ T cells in anti-
CD20 or placebo treated (Rituximab). Pathological grading (T-score) of allografts treated at 
four weeks. Ten micrographs at x200 magnification were analyzed (n=6, mean (SEM), Mann-
Whitney U test. *p<0.05; **p<0.01; ***p<0.001). (C) Transmission electron microscopy image 
of CAD kidney at 8 weeks post transplantation. T cell can be identified breaching the 
basement membrane and invading the renal tubule. 
 
Figure 8: B cells secrete fibrosis related cytokines. 
(A) Cytokine supernatant assay of isolated allograft (C57BL/6BM12!C57BL/6) B cells cultured 
for 72 hours alone or ionomycin (Ion.) and phorbitol mysirate (PMA) and compared to 
stimulated naïve B cells (n=6, mean (SEM), ANOVA and Bonferonni post hoc between pairs 
of groups. *p<0.05; **p<0.01; ***p<0.001). (B) Comparative quantification of mRNA fold 
difference by qRT-PCR in isolated allograft B cells compared to naïve spleen B cells, genes 
of interest normalized to two genes with 18s represented (n=8, assay in triplicate). 
 
Figure 9: Reduced fibrosis is associated with fewer macrophage and fibroblasts in the 
allograft (C57BL/6BM12!C57BL/6).  
(A) Representative immunohistochemistry of serial sections for type III collagen, F4/80, α-
Smooth Muscle Actin (α-SMA), SM22 (transgelin) and platelet derived growth factor receptor-
β (PDGFR-β). (B) Quantification of type III collagen, F4/80+ mononuclear cell infiltration, 
presence of α-SMA+ myofibroblast, PDGFR-β+ or transgelin+ fibroblast-like cells in anti-CD20 
or placebo (Rituximab) treated allograft treated at four weeks. Ten micrographs at x200 
magnification were analyzed (n=6, mean (SEM), Mann-Whitney U test. ***p<0.001). 
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Figure 10: B cells secrete profibrotic cytokines. 
(A) Cytokine supernatant assay of isolated allograft (C57BL/6BM12!C57BL/6) B cells cultured 
for 72 hours alone in media or ionomycin (Ion.) and phorbitol mysirate (PMA) or with γ-
irradiated C57BL/6BM12 splenocytes and compared to stimulated naïve B cells (n=6-8, assay 
in duplicate, mean (SEM), ANOVA and Bonferonni post hoc between pairs of groups. 
*p<0.05; **p<0.01). (B) Comparative quantification of mRNA fold difference by qRT-PCR in 
isolated allograft B cells compared to naïve spleen B cells, genes of interest normalized to 
two genes with 18s represented (n=8, assay in triplicate). 
 
Figure S1: CAD (C57BL/6BM12!C57BL/6) is not altered by B cell depletion prior to 
transplantation. 
Quantification of allograft density of collagen following picrosirius red staining following anti-
mouse anti-CD20 or anti-human anti-CD20 (Rituximab) 1 week prior to transplantation. 
Quantification of the number of tubules by haemotoxylin and eosin staining following 
treatment. Ten micrographs at x200 magnification were analyzed (n=6, mean (SEM), ANOVA 
and Bonferonni post hoc between pairs of groups. N.S.). 
 
Figure S2: Serum concentration of IgG subclasses. 
C57BL/6BM12 donor kidneys transplanted in to C57BL/6 allograft recipients 
(C57BL/6BM12!C57BL/6) or BALBc allograft recipients (C57BL/6BM12!BALB/c). Serum 
concentration of IgG subclasses from naïve and transplant recipient mice were measured 
(see Supplemental Table S1 for absolute values)(n=5, assay in duplicate, mean (SEM), 
ANOVA and Bonferonni post hoc between pairs of groups. *p<0.05; **p<0.01; ♯p<0.001 
against all groups). 
 
Figure S3: B cell depletion did not effect allograft (C57BL/6BM12!C57BL/6) neutrophil 
infiltration. 
(A) Intra-allograft Gr1+ neutrophils (hollow arrows) identified on immunohistochemistry 
(brown). (B). Quantification of the immunohistochemistry micrographs of allograft Gr1+ 
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neutrophils following treatment, ten micrographs at x200 magnification were analyzed (n=6, 
mean (SEM), ANOVA followed by Mann-Whitney U test. N.S ).  
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Supporting Information 
Additional Supporting Information may be found in the online version of this article. 
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Figure S1: CAD (C57BL/6BM12!C57BL/6) is not altered by B cell depletion prior to 
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Figure S2: Serum concentration of IgG subclasses 
Figure S3: B cell depletion did not effect allograft (C57BL/6BM12!C57BL/6) neutrophil 
infiltration 
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Figures 
 
 
Figure 1: B cells accumulate within transplanted kidneys undergoing chronic allograft 
damage (CAD)(C57BL/6BM12!C57BL/6).  
(A) Representative histology of paraffin-embedded allograft transplant kidney sections. 
Haemotoxylin and eosin for tissue architecture, collagen with picrosirius red (red), B220+ B 
cells (brown). (B) Quantification of the number of tubules, density of collagen and B cells in 
transplanted kidneys. Ten micrographs at x200 magnification were analyzed (n=6 mean 
(SEM), ANOVA and Bonferonni post hoc between groups at time points. *p<0.05; **p<0.01). 
(C) Definition of CAD B cell infiltrates 12 weeks post transplantation in immunofluorescent 
micrographs identifying GL7+ germinal centres and CD138+ plasma cells, and tertiary 
lymphoid tissue development with PNAd+ high endothelial venules and LYVE1+ lymphatic 
vessels.  
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Figure 2: The phenotype of allograft (C57BL/6BM12!C57BL/6) B cells by flow cytometry.  
(A) Gating of B cells from allograft kidney digest. Intra-allograft B cells isolated following 
allograft kidney digestion then B220+ magnetic bead enrichment prior to fluorescence 
activated cell sorting by B220+ CD45.2+ DAPI- for mRNA extraction and cell culture 
experiments. (B) CAD intra-allograft B cell phenotype were analysed on flow cytometry and 
compared to naive spleen B cells. (C) Frequency of gated B cells (n=6, mean (SEM), ANOVA 
and Bonferonni post hoc between groups. **p<0.01). 
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Figure 3: Anti-CD20 after transplantation depletes intra-renal B cells in chronic 
allograft damage (C57BL/6BM12!C57BL/6). 
(A) Flow cytometry gating of blood B cells prior to and following anti-mouse anti-CD20 or anti-
human anti-CD20 (Rituximab). (B) Absolute count of blood B cells were determined in mice 
treated prior to, or 4 weeks after, transplantation (n=6, mean (SEM), ANOVA and Bonferonni 
post hoc between groups at single time points. **p<0.01; ***p<0.001). (C) Quantification of 
the immunohistochemistry micrographs of allograft density of B220+ B cells following anti-
mouse anti-CD20 or anti-human anti-CD20 (Rituximab). Ten micrographs at x200 
magnification were analyzed (n=6 mean (SEM), Mann-Whitney U test. ***p<0.001). 
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Figure 4: B cell depletion reduces chronic allograft damage (C57BL/6BM12!C57BL/6). 
(A) Quantification of allograft density of collagen following picrosirius red staining following 
anti-mouse anti-CD20 or anti-human anti-CD20 (Rituximab). (B) Quantification of the number 
of tubules by haemotoxylin and eosin staining following treatment. Ten micrographs at x200 
magnification were analyzed (n=6, mean (SEM), Mann-Whitney U test between groups at 
single time points. *p<0.05; **p<0.01). (C) Allografts at 8 weeks after transplantation from 
mice depleted at 4 weeks of B cells had a decreased expression of CD20 and Kim-1 mRNA 
(n=8, assay in triplicate, mean (SEM), Mann-Whitney U test. *p<0.05). (D) Representative 
histology of paraffin-embedded transplant kidney sections. Fibrosis identified by collagen with 
picrosirius red, tubular atrophy demonstrated in untreated and placebo treated tissue. 
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Figure 5: Reduction in tertiary lymphoid tissue development. 
(A) Representative immunohistochemistry of GL7+ germinal centres (brown) counted per total 
tissue area section. (B) Absolute numbers of LYVE1+ lymphatic vessels (brown) per total 
tissue area section. (C) Absolute numbers of PNAd+ high endothelial venules (brown) per 
total tissue area section in anti-CD20 or placebo (Rituximab) treated allograft kidneys (n=6, 
mean (SEM), Mann-Whitney U test. *p<0.05). 
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Figure 6: CAD is not primarily mediated by donor-specific immunoglobulin. 
C57BL/6BM12 donor kidneys transplanted in to C57BL/6 allograft recipients 
(C57BL/6BM12!C57BL/6) or BALBc allograft recipients (C57BL/6BM12!BALB/c). (A) Serum 
concentrations of IgM and total IgG from naïve and transplant recipient mice were measured 
(see supplemental table 1 for absolute values)(n=5, assay in duplicate, mean (SEM), ANOVA 
and Bonferonni post hoc between groups. *p<0.05; **p<0.01; ♯p<0.001 against all groups). 
(B) Flow cytometry of live splenocytes incubated with transplant recipient serum to detect 
donor-specific IgG, quantification by median fluorescent intensity (n=6, assay in triplicate, 
error bars median and interquartile-range, ANOVA and Bonferonni post hoc between groups. 
***p<0.001). (C) Intra-allograft IgG content with representative immunofluorescence 
comparing naïve kidney and of CAD allograft 12 weeks post-transplantation demonstrating 
deposited IgG (green) and B cells bearing IgG. Quantification of IgG+ micrographs following 
treatment (n=6, mean ± SEM, Mann-Whitney U test, N.S.). 
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Figure 7: B cell depletion reduces T cell accumulation. 
(A) Representative immunohistochemistry of CD3+ infiltrating T cells (brown). T cells identified 
invading glomeruli (hollow arrows) and tubules (block arrows). (B) Quantification of the 
immunohistochemistry micrographs to determine allograft density of CD3+ T cells in anti-
CD20 or placebo treated (Rituximab). Pathological grading (T-score) of allografts treated at 
four weeks. Ten micrographs at x200 magnification were analyzed (n=6, mean (SEM), Mann-
Whitney U test. *p<0.05; **p<0.01; ***p<0.001). (C) Transmission electron microscopy image 
of CAD kidney at 8 weeks post transplantation. T cell can be identified breaching the 
basement membrane and invading the renal tubule. 
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Figure 8: B cells secrete fibrosis related cytokines. 
(A) Cytokine supernatant assay of isolated allograft (C57BL/6BM12!C57BL/6) B cells cultured 
for 72 hours alone or ionomycin (Ion.) and phorbitol mysirate (PMA) and compared to 
stimulated naïve B cells (n=6, mean (SEM), ANOVA and Bonferonni post hoc between pairs 
of groups. *p<0.05; **p<0.01; ***p<0.001). (B) Comparative quantification of mRNA fold 
difference by qRT-PCR in isolated allograft B cells compared to naïve spleen B cells, genes 
of interest normalized to two genes with 18s represented (n=8, assay in triplicate). 
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Figure 9: Reduced fibrosis is associated with fewer macrophage and fibroblasts in the 
allograft (C57BL/6BM12!C57BL/6).  
(A) Representative immunohistochemistry of serial sections for type III collagen, F4/80, α-
Smooth Muscle Actin (α-SMA), SM22 (transgelin) and platelet derived growth factor receptor-
β (PDGFR-β). (B) Quantification of type III collagen, F4/80+ mononuclear cell infiltration, 
presence of α-SMA+ myofibroblast, PDGFR-β+ or transgelin+ fibroblast-like cells in anti-CD20 
or placebo (Rituximab) treated allograft treated at four weeks. Ten micrographs at x200 
magnification were analyzed (n=6, mean (SEM), Mann-Whitney U test. ***p<0.001). 
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Figure 10: B cells secrete profibrotic cytokines. 
(A) Cytokine supernatant assay of isolated allograft (C57BL/6BM12!C57BL/6) B cells cultured 
for 72 hours alone in media or ionomycin (Ion.) and phorbitol mysirate (PMA) or with γ-
irradiated C57BL/6BM12 splenocytes and compared to stimulated naïve B cells (n=6-8, assay 
in duplicate, mean (SEM), ANOVA and Bonferonni post hoc between pairs of groups. 
*p<0.05; **p<0.01). (B) Comparative quantification of mRNA fold difference by qRT-PCR in 
isolated allograft B cells compared to naïve spleen B cells, genes of interest normalized to 
two genes with 18s represented (n=8, assay in triplicate). 
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Figure S1: CAD (C57BL/6BM12!C57BL/6) is not altered by B cell depletion prior to 
transplantation. 
Quantification of allograft density of collagen following picrosirius red staining following anti-
mouse anti-CD20 or anti-human anti-CD20 (Rituximab) 1 week prior to transplantation. 
Quantification of the number of tubules by haemotoxylin and eosin staining following 
treatment. Ten micrographs at x200 magnification were analyzed (n=6, mean (SEM), ANOVA 
and Bonferonni post hoc between pairs of groups. N.S.). 
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Figure S2: Serum concentration of IgG subclasses. 
C57BL/6BM12 donor kidneys transplanted in to C57BL/6 allograft recipients 
(C57BL/6BM12!C57BL/6) or BALBc allograft recipients (C57BL/6BM12!BALB/c). Serum 
concentration of IgG subclasses from naïve and transplant recipient mice were measured 
(see Supplemental Table S1 for absolute values)(n=5, assay in duplicate, mean (SEM), 
ANOVA and Bonferonni post hoc between pairs of groups. *p<0.05; **p<0.01; ♯p<0.001 
against all groups). 
 13 
 
 
 
 
Figure S3: B cell depletion did not effect allograft (C57BL/6BM12!C57BL/6) neutrophil 
infiltration. 
(A) Intra-allograft Gr1+ neutrophils (hollow arrows) identified on immunohistochemistry 
(brown). (B). Quantification of the immunohistochemistry micrographs of allograft Gr1+ 
neutrophils following treatment, ten micrographs at x200 magnification were analyzed (n=6, 
mean (SEM), ANOVA followed by Mann-Whitney U test. N.S ).  
 
